Individuals Stopping Anti-Obesity Medications Gain Back Weight Four Times Faster Compared to People Using Diet and Exercise

Fresh analysis reveals that patients who stop using blockbuster slimming jabs like Mounjaro or Wegovy can put back on reduced body mass much more quickly than those who stop traditional diet and exercise programs.

Research printed in a major health publication shows that while overweight people can lose a large proportion of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month after stopping.

"Individuals using these medications should be aware of the risk of quick weight regain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.

Such speed of recovery implies a return to original mass within about one and a half years.

Weighing Therapies

The analysis, which looked at dozens of studies involving thousands of patients, compared the outcomes of these new drugs with older methods.

Researchers emphasize that people who lose weight through diet and exercise generally experience a less rapid creep back—around 100 grams monthly—post-intervention.

Understanding the Rapid Rebound

Doctors suggest the mode of action of the injections explains the heightened regain.

These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.

"Sustained high doses of the hormone levels several times higher than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.

"Discontinuation of this medication leads to hunger is unsuppressed, making excessive eating much more probable."

A Chronic Condition?

The NHS recommend the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.

Many experts argue that, due to the significant potential of relapse, the therapy is often long-term.

This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the chronic nature of excess weight," comparing it to managing diseases like diabetes.

User Experiences

Individuals who have discontinued the jabs report a sudden resurgence of cravings.

"It felt as if a switch that goes on and you become starving," said one woman.

This difficulty is exacerbated if patients have not developed sustainable dietary or behavioural changes during treatment.

Widespread Interest

Survey data indicate that a significant number of people in the UK have tried these injections in the last 12 months, with interest continuing to grow.

• Use is more common among females compared to men.
• The middle-aged age group shows the highest usage rates.
• A large proportion obtain the medications through private healthcare rather than the NHS.

In conclusion, researchers caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and lasting health benefits relies on ongoing behavioural management.